COVID-19 has been the ongoing science topic discussed today, from treatment to research to economic impact, every aspect of the world is being affected by this mass virus. While there are many studies of vaccines, a new vaccine by China’s “Clover Biopharmaceuticals” has proved to have a reason for standing out amongst the other vaccines scientists have been creating.
This vaccine has given protection against five different variants of the strain, including the new destructive delta variant. It has also been shown to lower risk of disease in those who have, and have not been infected with COVID-19 before. Since the vaccine is based on SARS-CoV-2 protein, instead of mRNA products, the vaccine can be refrigerated instead of frozen. This shot also contains something called spike, an immune stimulant produced in hamster ovaries, which helps in boosting those who receive the vaccine immune system.
In Clover’s trial, 30,000 citizens from four different continents were observed after their vaccine was given to them. Those who did not have COVID-19 before had an efficacy of 67.2%, an efficacy of 83.7% regarding moderate to severe disease, and 100% efficacy when looking at hospitalization & death. Efficacy against the delta variant was 78.7%, while efficacy against a variant called Mu was only 58.6%.
For those who have had COVID-19 before, there was an efficacy of 64.2% in preventing another infection of COVID-19. This just so happens to be the first efficacy study that has been able to prove the importance of being vaccinated even when being exposed. Even though this is still a work in progress, this could be another big breakthrough for SARS-CoV-19 immunizations.
Posted by Emma Alderman-Shapiro (1)